Arno Therapeutics, Inc. reported unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported loss from operations of $3.863 million against $6.164 million a year ago. Net loss was $3.389 million or $0.17 per basic and diluted share compared to $0.446 million or $0.02 per basic and diluted share a year ago.

Adjusted non-GAAP net loss was $2.865 million or $0.14 per share against $4.988 million or $0.24 per share a year ago.